Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
CytoDyn
Biotech
CytoDyn finally clears FDA hold on HIV program after 2 years
In a short update Thursday, CytoDyn CEO Jacob Lalezari, M.D., heralded the lifting of the hold as a “new chapter” for lead asset leronlimab.
Annalee Armstrong
Feb 29, 2024 10:20am
Ex-Eisai leader to be new NextPoint CEO—Chutes & Ladders
Feb 2, 2024 9:30am
FDA promotes Bumpus to replace Woodcock—Chutes & Ladders
Dec 1, 2023 9:48am
Former Arena CEO takes over new RNA biotech—Chutes & Ladders
May 26, 2023 9:30am
Ex-CytoDyn CEO, Amarex CEO hit with multiple fraud charges
Dec 20, 2022 3:07pm
Fierce Biotech's Rotten Tomatoes of 2022
Dec 19, 2022 3:00am